A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers.
George F WohlfordLeo F BuckleyDinesh KadariyaTaeshik ParkJuan Guido ChiabrandoSalvatore CarboneVirginia MihalickMatthew S HalquistAdam PearcyDana AustinCohava GelberAntonio AbbateBenjamin W Van TassellPublished in: PloS one (2021)
A one-time treatment with SP16 for doses up to 0.2 mg/kg or 12 mg was safe in healthy volunteers.